Beta Bionics closes IPO, raising $234.6 million, focused on diabetes management solutions

From GlobeNewswire: 2025-01-31 17:56:42

Beta Bionics, Inc. announced the closing of its upsized initial public offering of 13.8 million shares of common stock, grossing approximately $212.1 million. The shares began trading on the Nasdaq Global Market under the ticker symbol “BBNX.” BofA Securities, Piper Sandler, and Leerink Partners were the lead bookrunners for the offering. In a concurrent private placement, Beta Bionics sold 1 million shares of its common stock at the same price, totaling around $229.1 million in gross proceeds. Beta Bionics is focused on developing advanced diabetes management solutions to improve the lives of insulin-requiring individuals.



Read more at GlobeNewswire: Beta Bionics Announces Closing of $234.6 Million Initial